Drugs / Cytisinicline
Cytisinicline
also known as
Cytisine · 6039 Sopharma · Baptitoxine · Citisiniclina · Cravv · Cytisine, Desmoxan · Cytiton · NSC-407282 · +3 more
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05981768 | Aug → Sep 2023 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05736224 | May → Sep 2023 | skin cancer | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT05631938 | Jan → Sep 2023 | impaired renal function disease | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05566288 | Oct → Dec 2022 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT03848208 | Feb → Sep 2019 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT03509948 | Apr → Jun 2018 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT03268343 | Aug 2017 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02585024 | Feb 2016 → Mar 2019 | — | University of Auckland, New Zealand | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03303911 | Oct 2017 → Oct 2018 | — | Achieve Life Sciences | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06617312 | Dec 2024 → Dec 2026 expected | nicotine dependence | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT05431387 | Jul 2022 → Feb 2023 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03654105 | Jul 2019 → Dec 2024 overdue | lung cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03709823 | Nov 2018 → Apr 2019 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06435221 | May 2024 → Sep 2025 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT05102123 | Jan 2024 → Jul 2026 overdue | nicotine dependence | Population Health Research Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05206370 | Jan 2022 → Mar 2023 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04576949 | Oct 2020 → Dec 2021 | — | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02957786 | Sep 2017 → Oct 2019 | — | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06579846 | Jan → Dec 2025 overdue | — | Maimónides Biomedical Research Institute of Córdoba | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05729243 | Feb 2023 → Dec 2025 | alcohol-related disorders, nicotine dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 4 | NCT04126135 | Jan 2022 → Mar 2024 | nicotine dependence | Loma Linda University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04286295 | Mar 2022 → Nov 2023 | coronary artery disorder | Ottawa Heart Institute Research Corporation | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02797587 Comparator | Jul 2017 → Apr 2020 | HIV infectious disease, alcohol-related disorders | Boston Medical Center | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07392125 Comparator | May → Nov 2026 expected | — | Achieve Life Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05311085 Comparator | May 2022 → May 2024 | — | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 3 | NCT04015414 Comparator | Jul 2020 → Sep 2022 | — | University of Zagreb | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06832085 Comparator | Apr 2025 → Apr 2027 expected | — | Ottawa Heart Institute Research Corporation | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03249428 Comparator | Nov 2025 → Mar 2027 expected | bronchial disorder, mental disorder, nicotine dependence | Ottawa Hospital Research Institute | Enrolling by invitation | No outcome recorded |
| — | NCT06945770 Background | May 2024 → Jan 2025 | — | Ege University | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytisinicline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06617312 ↗ |
| Known as | 6039 Sopharma | ChEMBL registry synonym — accepted as the source's own label CHEMBL497939 ↗ |
| Known as | Baptitoxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL497939 ↗ |
| Known as | Citisiniclina | ChEMBL registry synonym — accepted as the source's own label CHEMBL497939 ↗ |
| Known as | Cravv | “In Canada, cytisine is marketed as the natural health product Cravv™.” NCT04286295 ↗ |
| Known as | Cytisine | “The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and...” NCT05736224 ↗ |
| Known as | Cytisine, Desmoxan | “Cytisine, Desmoxan” NCT02585024 ↗ |
| Known as | Cytiton | ChEMBL registry synonym — accepted as the source's own label CHEMBL497939 ↗ |
| Known as | NSC-407282 | ChEMBL registry synonym — accepted as the source's own label CHEMBL497939 ↗ |
| Known as | Sophorine | ChEMBL registry synonym — accepted as the source's own label CHEMBL497939 ↗ |
| Known as | Tabex | “Cytisine (Tabex)” NCT04015414 ↗ |
| Known as | Ulexine | ChEMBL registry synonym — accepted as the source's own label CHEMBL497939 ↗ |
| Action | Activate | “Cytisine, a partial agonist for the α4β2-nAChR” PMID 30526213 ↗ Jun 2019 |
| Modality | Small molecule | “Cytisine is a naturally occurring alkaloid” NCT03249428 ↗ |
| Route | Oral | “single oral dose of 1.5, 3 or 4.5 mg of cytisine” PMID 30526213 ↗ Jun 2019 |